HomeCompareCAKFY vs EPRT

CAKFY vs EPRT: Dividend Comparison 2026

CAKFY yields 4.15% · EPRT yields 3.97%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EPRT wins by $39.0K in total portfolio value
10 years
CAKFY
CAKFY
● Live price
4.15%
Share price
$4.10
Annual div
$0.17
5Y div CAGR
-2.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$408.34
Full CAKFY calculator →
EPRT
EPRT
● Live price
3.97%
Share price
$30.36
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$64.3K
Annual income
$13,170.85
Full EPRT calculator →

Portfolio growth — CAKFY vs EPRT

📍 EPRT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCAKFYEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CAKFY + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CAKFY pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CAKFY
Annual income on $10K today (after 15% tax)
$352.44/yr
After 10yr DRIP, annual income (after tax)
$347.09/yr
EPRT
Annual income on $10K today (after 15% tax)
$337.37/yr
After 10yr DRIP, annual income (after tax)
$11,195.22/yr
At 15% tax rate, EPRT beats the other by $10,848.13/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CAKFY + EPRT for your $10,000?

CAKFY: 50%EPRT: 50%
100% EPRT50/50100% CAKFY
Portfolio after 10yr
$44.8K
Annual income
$6,789.60/yr
Blended yield
15.14%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

CAKFY
No analyst data
Altman Z
4.1
Piotroski
6/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+16.9% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CAKFY buys
0
EPRT buys
0
No recent congressional trades found for CAKFY or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCAKFYEPRT
Forward yield4.15%3.97%
Annual dividend / share$0.17$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-2.5%29%
Portfolio after 10y$25.4K$64.3K
Annual income after 10y$408.34$13,170.85
Total dividends collected$4.1K$38.7K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: CAKFY vs EPRT ($10,000, DRIP)

YearCAKFY PortfolioCAKFY Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$11,104$404.27$11,212$512.01$108.00EPRT
2$12,291$409.05$12,689$692.09$398.00EPRT
3$13,564$412.56$14,521$944.30$957.00EPRT
4$14,928$414.86$16,841$1,302.88$1.9KEPRT
5$16,389$416.05$19,841$1,821.64$3.5KEPRT
6$17,952$416.22$23,818$2,587.47$5.9KEPRT
7$19,624$415.45$29,230$3,744.65$9.6KEPRT
8$21,412$413.82$36,816$5,540.38$15.4KEPRT
9$23,322$411.43$47,806$8,413.17$24.5KEPRT
10$25,363$408.34$64,324$13,170.85$39.0KEPRT

CAKFY vs EPRT: Complete Analysis 2026

CAKFYStock

McKesson Europe AG provides logistics and other services to the pharmaceutical and healthcare sectors worldwide. The company operates through two divisions, Pharmaceutical Distribution and Retail Pharmacy. The Pharmaceutical Distribution division engages in the wholesale of pharmaceutical and other health care products. This division serves its customers through 90 wholesale branches that supply pharmaceutical products to approximately 40,000 pharmacies and hospitals, as well as operates 70 distribution centers in Europe. The Retail Pharmacy division operates approximately 2,000 owned pharmacies and approximately 8,000 members in its brand partnership program. This division also provides outpatient drug, e-commerce, and home care services primarily in Belgium, Ireland, Italy, and the United Kingdom under the Lloyds Pharmacy brand. In addition, this division provides traditional prescription drugs, over-the-counter products, and medical services. It also provides other services for pharmacists, such as the organization and management of pharmacy cooperation programs in the Great Britain, France, Portugal, and Belgium. The company was formerly known as Celesio AG and changed its name to McKesson Europe AG in September 2017. The company was founded in 1835 and is headquartered in Stuttgart, Germany. McKesson Europe AG is a subsidiary of McKesson Corporation.

Full CAKFY Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this CAKFY vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CAKFY vs SCHDCAKFY vs JEPICAKFY vs OCAKFY vs KOCAKFY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.